PLEASE NOTE ALL AGENDA TIMES, SPEAKERS AND TOPICS ARE SUBJECT TO CHANGE UNTIL FINAL AGENDA IS CONFIRMED
Registration
Primary Care Conference
Family care clinicians are the first line of defense for patients suffering from IBS, a common disorder that causes substantial reduction in health-related quality of life. The diagnosis of IBS, whether it is IBS-D, IBS-M, or IBS-C, is generally made clinically, which is impacted by recent changes in the Rome criteria. Now recognized as both a brain-gut and a gut-brain disorder, the treatment of patients with IBS has evolved significantly in the past year. Understanding the patient burden of disease, particularly symptoms that are most troublesome, is helpful in individualizing therapy. The 2018 American College of Gastroenterology IBS guidelines lend clarity to treatments found effective, including soluble fiber and several medications, while finding little evidence to support the use of therapies such as a gluten-free diet, prebiotics/probiotics/synbiotics, and antispasmodics.
Presentation presented by the Primary Care Education Consortium (PCEC). You will receive a certificate of participation for this activity. ANCC accepts AAFP Prescribed credit. and AMA PRA Category 1 Credits. Grant funded by Salix Pharmaceuticals, Inc.
Renal and Cardiovascular Outcomes in Patients with Diabetic Nephropathy (ie, Diabetic Kidney Disease) and Type 2 Diabetes
This session is provided by a commercial interest. Contact Hours will not be awarded.
The management of patients with T2DM has undergone a seismic shift from a glucose- centric to a patient-centric focus with a primary goal of reducing cardiovascular risk. The shift to focus on cardiovascular risk stems not only from the fact that microvascular and macrovascular complications continue to be common in persons with type 2 diabetes mellitus, but also from evolving evidence clearly demonstrating cardiovascular risk reduction with some antidiabetic medications. To reduce the burden of disease and improve the journey of persons with type 2 diabetes, however, requires understanding the evidence base for these benefits and differences among the antidiabetic medications, and how treatment can be individualized to address the unmet needs of each patient.
Presentation presented by the Primary Care Education Consortium (PCEC). You will receive a certificate of participation for this activity. ANCC accepts AAFP Prescribed credit. and AMA PRA Category 1 Credits. Grant funded by Lilly.
The pharmacologic treatment of diabetic kidney disease (DKD) has typically involved treatment of associated risk factors such as blood glucose, blood pressure, and the use of medications that act on the renin-angiotensin-aldosterone system. Recently, a variety of glucose-lowering medications have been investigated to assess their potential for improved renal outcomes in patients with type 2 diabetes mellitus and with/without established DKD. Several of these medications have been shown to improve renal outcomes in patients with type 2 diabetes mellitus. This presentation seeks to provide insight into the results of these clinical trials and how the selected medications can be used to individualize therapy as recommended in updated guidelines issued by the American Diabetes Association and the American Association of Clinical Endocrinologists/ American College of Endocrinology.
Presentation presented by the Primary Care Education Consortium (PCEC). You will receive a certificate of participation for this activity. ANCC accepts AAFP Prescribed credit and AMA PRA Category 1 Credits. Sponsored by PCEC and PCMG Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc
Pharmacology Conference
Supporter Statement: This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
Provider Statement: This continuing nurse education activity is provided by Vindico Medical Education.
By completing this session, participants will be able to apply new evidence into practice regarding the use of diagnostic testing, treatment and chemoprophylaxis for people with, or at risk for, influenza. Also, Incorporate the use of antiviral agents into practice based on their ability to reduce transmission, as well as treat people with influenza who are at normal or high risk for complications.Content Developed by: John J. Russell, MD, Clinical Professor of Family and Community Medicine, Thomas Jefferson University Sidney Kimmel School of Medicine, Philadelphia, PA; Chair, Department of Family Medicine and Program Director, Family Medicine Residency, Abington – Jefferson Health, Abington, PAThis activity is supported by an educational grant from Genentech, Inc.This continuing nurse education activity is provided by Vindico Medical Education.